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CLINICAL INVESTIGATIONS

A comprehensive meta-analysis of stem cell therapy for
chronic angina
Rahman Shah1
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Background: A substantial proportion of patients with coronary artery disease do not achieve

2

complete revascularization and continue to experience refractory angina despite optimal medi-
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cal therapy. Recently, stem cell therapy has emerged as a potential therapeutic option for these
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patients. However, findings of individual trials have been scrutinized because of their small
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meta-analysis of available randomized controlled trials (RCTs) with the largest sample size ever

sample sizes and lack of statistical power. Therefore, we conducted an updated comprehensive
reported on this subject.
Hypothesis: In patients with chronic angina stem cell therapy improves clinical outcomes.
Methods: Scientific databases and websites were searched for RCTs. Data were independently
collected by 2 investigators, and disagreements were resolved by consensus. Data from 10 trials
including 658 patients were analyzed.
Results: Stem cell therapy improved Canadian Cardiovascular Society angina class (risk ratio:
1.53, 95% CI: 1.09 to 2.15, P = 0.013), exercise capacity (standardized mean difference [SMD]:
0.56, 95% CI: 0.23 to 0.88, P = 0.001), and left ventricular ejection fraction (SMD: 0.63, 95%
CI: 0.27 to 1.00, P = 0.001) compared with placebo. It also decreased anginal episodes (SMD:
–1.21, 95% CI: –2.40 to −0.02, P = 0.045) and myocardial perfusion defects (SMD: –0.70, 95%
CI: –1.11 to −0.29, P = 0.001). However, no improvements in all-cause mortality were
observed after a relatively short follow-up.
Conclusions: In patients with chronic angina on optimal medical therapy, stem cell therapy
improves symptoms, exercise capacity, and left ventricular ejection fraction. These findings
warrant confirmation using larger trials.
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1 | I N T RO D UC T I O N

statistical power. Therefore, we conducted an updated comprehensive meta-analysis of available RCTs.

The number of patients diagnosed with severe coronary artery disease is increasing because of improved survival rates and an aging
population.1 Despite continued developments and improvements in

2 | METHODS

treatments that facilitate myocardial revascularization, a substantial
proportion of these patients do not achieve complete revascularization and continue to experience refractory angina despite optimal

2.1 | Data sources and searches

medical therapy (OMT).1 Recently, several small randomized clinical

This meta-analysis was performed according to the guidelines of Pre-

trials (RCTs) suggested that stem cell therapy may be a potential ther-

ferred Reporting Items for Systematic Reviews and Meta-Analyses

apeutic option for these patients.2–11 However, individual trials have

(PRISMA).12 We performed computerized literature searches of the

been criticized for their small sample sizes and resulting lack of

PubMed, http://www.Clinicaltrials.gov, and Cochrane databases from
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FIGURE 1

Search flow diagram

their respective inceptions to November 2017 without language

heterogeneity across trials using the Cochran Q test and the Higgins

restrictions. Searches were performed on various combinations of the

I2 test.14 When heterogeneity was discovered, a sensitivity analysis

following terms: “cell therapy,” “stem cell,” “angina,” “ischemic heart

was performed by excluding 1 study at a time and evaluating the

disease,” and “clinical trial.” In addition, abstracts from major interna-

impact on the summary results.15 Publication bias was not assessed

tional cardiology scientific meetings were reviewed. We also con-

because the number of included trials was inadequate to properly

tacted corresponding authors for those articles not reporting mean

assess a funnel plot or to use more advanced regression-based

values for continuous variables.

assessments.16
The authors are solely responsible for the design and conduct of

2.2 | Data extraction and quality assessment
RCTs were included if patients suffering from angina despite OMT
were randomly assigned to either stem cell therapy or placebo treat-

this study, all study analyses, the drafting and editing of the manuscript, and its final contents. No extramural funding was used to support this work.

ment. The data were independently collected by 2 investigators, and
disagreements were resolved by consensus. The potential risk of bias

3 | RE SU LT S

of RCTs was appraised according to the Cochrane Collaboration
guidelines.13

Ten RCTs including 658 patients (386 in cell groups and 272 in pla-

The primary efficacy endpoints were changes in Canadian Car-

cebo groups) met our inclusion criteria.2–11 All included RCTs were

diovascular Society (CCS) angina class, anginal frequencies, and exer-

blinded. The search flow diagram is shown in Figure 1. Table 1

cise capacity. The secondary efficacy endpoints were left ventricular
ejection fraction (LVEF) and myocardial perfusion defects (summed

describes the characteristics of each individual trial. The majority of
these trials were multicenter, but they included only a small number

score) identified using single-photon emission computed tomography

of patients. Four studies used CD34+ cells, 3 used bone marrow

(SPECT). Study definitions were used for the outcome data.

mononuclear cells, 2 used CD133+ cells, and 1 used adipose-derived
stem cells. The techniques used to harvest these cells varied among

2.3 | Data synthesis and analysis

the studies. The follow-up duration was 6 months in 5 studies,

This meta-analysis was performed using the Comprehensive Meta-

12 months in 4 studies, and 24 months in 1 study.

Analysis system, version 3 (Biostat, Inc., Englewood, NJ). For dichoto-

In patients suffering from chronic angina, stem cell therapy

mous variables, pooled risk ratios (RRs) were calculated using a

decreased anginal episodes (SMD: –1.21, 95% CI: –2.40 to −0.02,

random-effects model. For continuous variables, the data were sum-

P = 0.045) compared with the placebo-treated group (Figure 2). How-

marized as the standardized mean difference (SMD) because the

ever, significant between-trial heterogeneity was found (Cochran's

measurement units for some of the outcomes varied across studies.

Q = 115.8, P < 0.001, I2 = 96.54%). Sensitivity analysis suggests that

Because the trials by Pokushalov and Henry enrolled predominantly

heterogeneity originated from the study by Wang, which was a

ischemic cardiomyopathy patients, additional sensitivity studies were

single-center study performed in China.4 Removing this trial elimi-

5,8

nated the heterogeneity (Cochran's Q = 2.9, P = 0.39, I2 = 0.00%)

performed excluding both trials.

We evaluated the presence of

Efficacy: angina
Primary: ETT. Primary: MPI.
frequency, CCS
Secondary:
Secondary:
class, ETT, MPI,
LVEF, CCS,
CCS, LVEF.
QOL. Safety:
MPI
Safety:
arrhythmia,
arrhythmia,
LVEF
MI

Endpoints

6

12

41 × 106

PTE

BMMNC

Echo

26

27

76

71

100

100

85

87

62

61

54

55

SC

12

1 × 105, 5 × 105a

PTE

CD34+

SPECT

59

59

96

91

75

79

89

86

61

60

56

111

MC

Losordo,
2011

6

30 × 106

PTE

CD133+

SPECT, echo

55

51

NR

NR

67

68

100

79

58

70

9

19

MC

12

40–80 × 106

PTE

ADRC

Echo

31

31

71

77

100

82

93

94

65

64

14

17

MC

Jimenez-Quevedo,
2014
Henry, 2016

24

1 × 105 to
1 × 107

PTE

CD34+

NR

52

52

82

91

56

41

86

80

64

64

28

50

MC

Posvic,
2016

12

2.8 × 106 and
5.3 × 106

PTE

CD133+

MRI, SPECT

53

48

80

81

73

63

11

12

61

64

15

16

SC

Wojakowski,
2017

Efficacy: angina
Primary: MPI. Primary: angina
Efficacy: angina
Efficacy: Angina
Efficacy:
Primary: MPI.
frequency,
Secondary:
frequency.
frequency, CCS,
frequency, CCS,
Secondary:
angina
CCS, ETT, MPI.
arrhythmia,
Secondary: ETT,
ETT, LVEF, MPI.
ETT, LVEF, QOL,
frequency,
CCS, LVEF
Safety:
CCS, LVEF,
use of antianginal
Safety: MACE,
VO2max. Safety:
ETT.
arrhythmia,
mortality.
medication, CCS,
MACVE
arrhythmia,
Secondary:
LVEF
Safety: CCS,
QOL
MACE
arrhythmia,
LVEF
MACE

6

5.6 × 107

IC

CD34+

SPECT

NR

NR

2

3

11

9

52

50

61

61

56

56

SC

Pokushalov,
2010

a

55 patients used low-dose cells (1 × 105) and 56 patients received high-dose cells (5 × 105).

Abbreviations: ADRC, adipose-derived regenerative cell(s); BMMNC, bone marrow mononuclear cell(s); CABG, coronary artery bypass grafting; CCS, Canadian Cardiovascular Society; echo, echocardiogram; ETT, exercise tolerance test; Hx, history of; IC, intracoronary; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events; MACVE, major adverse cerebrovascular events; MC, multicenter; MI, myocardial
infarction; MPI, myocardial perfusion imaging; MRI, magnetic resonance imaging; NR, not reported; PTE, percutaneous transendocardial; QOL, quality of life; SC, single center; SPECT, single-photon emission computed tomography; VO2max, maximum oxygen consumption.

6

6

100 × 106

PTE

Follow-up
duration, mo

PTE

PTE

5 × 104, 1 × 105, 1 × 106,
5 × 105
2 × 106

Mean dose of cells

BMMNC

Cardiac MRI

54

56

76

96

72

56

80

92

62

64

25

25

SC

Van Ramshorst, Wang,
2009
2010

Route of injection

BMMNC

CD34+

Type of cell

45
Cardiac MRI

NR

Echo

Placebo

63

68

NR

NR

88

51

66

68
79

NR

Placebo

Cell

94

50

Placebo

Cell

61

NR

Cell

Placebo

NR

NR

Cell

65

9

19

MC

Tse,
2007

Methods for LVEF estimation

Baseline LVEF, %

Hx of CABG, %

Hx of MI, %

Male sex, %

Placebo

6

Placebo

NR

18

Sample size, n

Cell

MC

Cell

Study type

Mean age, y

Losordo,
2007

Baseline characteristic of included trials

Characteristic

TABLE 1
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FIGURE 2

SHAH ET AL.

(A) Improvement in anginal episodes from baseline to the longest follow-up time point. (B) Individual and pooled RRs for
improvements in CCS angina class. (C) Improvement in exercise capacity from baseline to the longest follow-up time point. The size of the
square represents the relative impact of the corresponding study on the overall estimate. The overall summary estimate for the analysis is
marked with a diamond. The width of the diamond represents the 95% CI. Abbreviations: CCS, Canadian Cardiovascular Society; CI, confidence
interval; df, degrees of freedom; RR, risk ratio; std diff, standard difference
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FIGURE 3

(A) Improvements in perfusion defects (by SPECT) from baseline to the longest follow-up time point. (B) Improvement in LVEF.
(C) Individual and pooled RRs for all-cause mortality. Abbreviations: CI, confidence interval; df, degrees of freedom; LVEF, left ventricular
ejection fraction; RR, risk ratio SPECT, single-photon emission computed tomography; std diff, standard difference

without affecting summary results (SMD: –0.44, 95% CI: –0.66 to

95% CI: 1.09 to 2.15, P = 0.013; Figure 2). There was no significant

−0.21, P < 0.001). On the other hand, removing any other trial did

heterogeneity between the trials (Q = 0.8, P = 0.93, I2 = 0.00%).

not eliminate heterogeneity.

Stem cell treatment also increased exercise capacity (SMD: 0.56,

Similarly, significantly more patients in the stem cell–treated

95% CI: 0.23 to 0.88, P = 0.001) compared with the placebo-treated

group displayed improvements in their CCS angina class (RR: 1.53,

group (Figure 2). Again, significant heterogeneity was found
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TABLE 2

Incidence of serious adverse events by trial

Author, Year

Cell Groups

Placebo

Losordo, 2007

A-arrhythmia, 1; CHF, 16; respiratory arrest, 11; CVA, 5;
bleeding/anemia, 16; electrolytes disorder, 16

A-arrhythmia, 33; V-arrhythmia, 1

Tse, 2007

NR

NR

Van Ramshorst, 2009

CHF, 4

PE, 4; CVA, 4; infection, 4; breast cancer, 4

Wang, 2010

A-arrhythmia, 2; V-arrhythmia, 2; angina exacerbation,
3; CVA, 2; endocrine/electrolyte disorder, 2

A-arrhythmia, 3; V-arrhythmia, 2; angina
exacerbation, 5; endocrine/electrolyte disorder, 2

Pokushalov, 2010

NR

NR

Losordo, 2011

MI, 5; MACE, 12; stroke, 3; cardiac hospitalization
or ED visit, 32

MI, 12; MACE, 26; stroke, 1; cardiac hospitalization
or ED visit, 37

Jimenez-Quevedo, 2014

MACE and MACVE, 10; sustained VT/VF, 5; PE, 5;
repeat hospitalization for cardiac cause, 11

MACE and MACVE, 11; sustained VT/VF, 11;
repeat hospitalization for cardiac cause, 25

Henry, 2016

MACE, 35; MI, 5; stroke/TIA, 11; CHF hospitalization, 11

MACE, 21; stroke/TIA, 7; CHF hospitalization, 21

Posvic, 2016

MACE, 42; MI, 10; CV hospitalization, 32; V-arrhythmia, 7

MACE, 67; MI, 7; CV hospitalization, 64; V-arrhythmia, 3

Wojakowski, 2017

PFA, 6; UA, 6

DVT, 6; UA, 6

Abbreviations: A-arrhythmia, atrial arrhythmia; CHF, congestive heart failure; CV, cardiovascular; CVA, cerebrovascular accident; DVT, deep venous
thrombosis; ED, emergency department; MACE, major adverse cardiac events; MI, myocardial infarction; NR, none reported; PE, pericardial effusion;
PFA, pseudoaneurysm of femoral artery; TIA, transient ischemic attack; UA, unstable angina; V-arrhythmia, ventricular arrhythmia; VF, ventricular fibrillation; VT, ventricular tachycardia. Data are presented as %.

(Cochran's Q = 14.6, P = 0.022, I2 = 59.14%), originating from the

stem cells act appears to be through the secretion of paracrine fac-

study by Wang. Removing this study eliminated heterogeneity

tors that have cryoprotective and angiogenic effects.17

(P = 0.52, I2 = 0.00%) without affecting summary results (SMD: 0.39,

Several small-sized RCTs and meta-analyses have suggested that
stem cell therapy may improve symptoms in patient with chronic

95% CI: 0.17 to 0.61, P < 0.001).
Stem cell therapy also improved LVEF (SMD: 0.63, 95% CI: 0.27

angina.2–10,18,19 However, since those meta-analyses, several new

to 1.00, P = 0.001; Figure 3). However, no effects on all-cause mor-

RCTs have been reported, arguably rendering those meta-analyses

tality were found (RR: 0.47, 95% CI: 0.183 to 1.22, P = 0.121;

outdated.8–10 Our updated, comprehensive meta-analysis (consisting

Figure 3). No between-trial heterogeneity was found for any of these

of the largest sample size ever reported) showed that, in patients

outcomes.

with chronic angina, stem cell therapy improved symptoms and exer-

Finally, sensitivity analyses excluding the studies by Pokushalov

cise capacity. It also decreased perfusion defects measured by

In

SPECT. In addition, stem cell therapy was associated with a statisti-

addition, the incidence of adverse effects with stem cell therapy was

cally significant improvement in LVEF. However, in the majority of

low, as shown in Table 2.

these trials, global left ventricular systolic function was preserved,

and Henry did not change our summary results or conclusion.

5,8

and the absolute improvement in LVEF with stem cell therapy was
small. Finally, because of the small sample sizes of these trials and

4 | DISCUSSION
In this meta-analysis of 10 RCTs, we evaluated the efficacy of stem

shorter follow-up periods, no definite conclusion can be made about
the impact of stem cell therapy on mortality. Therefore, additional trials with larger sample sizes and longer follow-ups are needed.

cell therapy in patients suffering from chronic angina. We found that
stem cell therapy improved the CCS angina class and decreased

4.1 | Study limitations

angina frequency during 6 to 24 months of follow-up. The stem cell

This meta-analysis has several limitations. First, we did not have indi-

therapy also improved exercise capacity, perfusion defects (observed

vidual participant data; data from various studies were combined.20

via SPECT), and LVEF.

Each study had its own protocol and definitions as well as follow-up

Despite continued developments and improvements in treat-

duration. Specifically, the type of stem cell, number of stem cells, and

ments facilitating myocardial revascularization, about 5% to 15% of

delivery method varied across studies. However, because small num-

patients do not achieve complete revascularization and continue to

bers of patients participated in each trial, subgroup analyses to deter-

experience refractory angina despite OMT.1 Although it results in low

mine the relative efficacy between certain types of cells or routes of

mortality, refractory angina is a debilitating condition. Thus, a new

administration were not performed. Therefore, additional studies

therapy is needed for these patients. Recently, stem cell therapy has

must be conducted to compare cell types and routes of administra-

emerged as a potential therapeutic option for these patients.1 Stem

tion. Similarly, the definition of major adverse cardiac events varied

cell therapy is thought to improve myocardial perfusion and angina

across the studies, so we could not report on the effects related to

by promoting neovascularization.1 This may be partly due to the

the major adverse cardiac events rate. In addition, not all studies

capacity of stem cells to differentiate into endothelial cells and

reported data about the class of angina and the number of episodes

smooth muscle.1 However, the predominant mechanism by which

of angina; we were accordingly unable to include data from all of the

SHAH ET
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trials to estimate the pooled effect of stem cell on anginal symptoms.
Finally, because the sample sizes of these trials were small, our findings are hypothesis-generating, and additional trials with larger samples are needed. Despite these limitations, this is the most
comprehensive meta-analysis with the largest sample size ever
reported on this subject.

5 | CO NC LUSIO N
In patients suffering from chronic angina, stem cell therapy significantly improves symptoms, exercise capacity, and LVEF compared
with placebo-treated groups. It also decreases myocardial perfusion
defects. These findings warrant further studies in a larger clinical trial
in the future.
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